Abstract: Engineered bispecific antibodies with charge pairs introduced at the interface of CHI and CL alone or in combination with other charge pairs at the interface of VH and VL are described. Also described are anti-CD47/anti-CLDN18.2 and anti-CD3/anti-DLL3 bispecific antibodies and antigen-binding fragments thereof. Also described are nucleic acids encoding the bispecific antibodies, compositions comprising the bispecific antibodies, and methods of producing the bispecific antibodies and using the bispecific antibodies for treating or preventing diseases, such as cancer and/or associated complications.

Abstract: Provided is a node diaphragm scraping and sorting device for a bamboo split, which is configured to scrape node diaphragms of the bamboo splits and to sequentially sort the bamboo inner layers and bamboo outer layers of the bamboo splits towards the same direction. The device includes a scraping device, a sorting device and a clamping and conveying device which are arranged from front to back along an axis. The scraping device includes a conical cylinder, two pressing semi-rings, and a scraping ring. The sorting device includes an e-shaped sleeve composed of an inner cylinder and an outer cylinder, and two shifting forks located at both ends of the sleeve. The clamping and conveying device includes an inner ring moving on the axis, two clamping semi-rings and a conveying power device. The structure, function and technical parameters of each branch device are also introduced in detail.

Abstract: Anti-FOLR1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.

Abstract: Anti-TAA antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer and/or an inflammatory disease.

Abstract: Monoclonal antibodies (mAbs) or bispecific antibodies (bsAbs) or multi-specific antibodies comprising a fatty acid (FA) molecule conjugated to or near the antigen-binding domain are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases, such as cancer and/or associated complications.

Abstract: Anti-CLDN18.2 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer and/or an inflammatory disease.

Abstract: Engineered bispecific antibodies with shifted interchain disulfide bond on one arm while maintaining the native interchain disulfide bond on the second arm are described. Also described are anti-CD47/FR? bispecific antibodies and antigen-binding fragments thereof. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases, such as cancer and/or associated complications.

Abstract: Anti-CD47 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, inflammatory disease, infectious disease, atherosclerosis, cardiovascular disease, metabolic disease, radiation-induced injury, and/or autoimmune disease.

Abstract: Anti-LAG-3 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, an inflammatory disease, an autoimmune disease, type 1 diabetes, and/or infectious diseases.

Abstract: Anti-apelin antibodies and antigen-binding fragments thereof are described.

Abstract: Chimeric antigen receptors (CARs) specific to CLDN18.2, vectors encoding the CLDN18.2 CAR, recombinant host cells comprising the CLDN18.2 CAR (CAR-Ts or CAR-NKs), and methods of using the CAR-Ts or CAR-NKs to treat a disease associated with the expression of CLDN18.2 thereof are described.

Abstract: Chimeric antigen receptors (CARs) specific to DLL3, vectors encoding the DLL3 CAR, recombinant host cells comprising the DLL3 CAR (CAR-Ts or CAR-NKs), and methods of using the CAR-Ts or CAR-NKs to treat a disease associated with the expression of DLL3 thereof are described.

Abstract: Chimeric antigen receptors (CARs) specific to FOLR1, vectors encoding the FOLR1 CAR, recombinant host cells comprising the FOLR1 CAR (CAR-Ts or CAR-NKs), and methods of using the CAR-Ts or CAR-NKs to treat a disease associated with the expression of FOLR1 thereof are described. Humanized anti-FOLR1 monoclonal antibodies and antigen-binding fragments thereof are also described.

Abstract: Anti-TIP-1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.

Abstract: Anti-CD73 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer.

Abstract: Anti-TIM-3 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, an inflammatory disease, an autoimmune disease, a metabolic disease, and/or infectious diseases.

Abstract: Anti-DLL3 antibodies and antigen-binding fragments thereof, anti-CD47 antibodies and antigen-binding fragments thereof, and anti-CD47/DLL3 bispecific antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases, such as cancer and/or associated complications.

Abstract: Anti-LAG-3 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, an inflammatory disease, an autoimmune disease, type 1 diabetes, and/or infectious diseases.

Abstract: Anti-TIM-3 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, an inflammatory disease, an autoimmune disease, a metabolic disease, and/or infectious diseases.

Abstract: Anti-FOLR1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.